As treatment options expand in chronic lymphocytic leukemia (CLL), the benefits and limitations of fixed-duration regimens in ...
Dr Thomas Flaig from the University of Colorado Anschutz discusses a paradigm shift in treating urothelial carcinoma patients ...
The FDA granted fast track designation to PAS-004, a macrocyclic MEK inhibitor, for NF1-associated plexiform neurofibromas ...
According to a recent systematic review published in JCO Oncology Practice, implementation of same-day multidisciplinary ...
The study investigated r ezatapopt (PC14586), a first-in-class small molecule designed to selectively bind and reactivate the ...
The FDA has granted traditional approval to brexucabtagene autoleucel (Tecartus; brexu-cel) for treatment of adult patients ...
The investigators note that the lower rate of feeding-tube placement with IMPT at the end of treatment, combined with a ...
At the 2026 European Lung Cancer Congress (ELCC), Dr Nicolas Girard discussed updated data from the PALOMA-2 study, which ...
The Centers for Medicare & Medicaid Services has issued a permanent billing and reimbursement J-code, J9183, for the ...
The FDA granted breakthrough therapy designation to plixorafenib for adult patients with BRAF V600E–mutated high-grade glioma ...
Victoria Rizk, MD, explores genomic assays to refine adjuvant therapy and capture clinical real-world evidence in breast ...
In an interview with Targeted Oncology, Pavlos Msaouel, MD, PhD, at The University of Texas MD Anderson Cancer Center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results